Valion Bio Inc Total Liabilities
Valion Bio Inc total liabilities. Based on the latest financial reports, Valion Bio Inc (VBIO) has total liabilities worth $20.59 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See how many days can Valion Bio Inc fund operations to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Valion Bio Inc (2010–2025)
Total liabilities of Valion Bio Inc from 2010 to 2025. This chart illustrates how Valion Bio Inc's total liabilities have evolved over time, based on quarterly financial data.
Valion Bio Inc Competitors by Total Liabilities
The table below lists competitors of Valion Bio Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Oxford Metrics plc
LSE:OMG
|
UK | GBX17.52 Million |
|
Redan S.A.
WAR:RDN
|
Poland | zł34.61 Million |
|
Groupimo SA
PA:ALIMO
|
France | €1.26 Million |
|
Churchill China plc
LSE:CHH
|
UK | GBX15.76 Million |
|
EGR EXPL LTD
F:Z0R
|
Germany | €231.51K |
|
GetBusy PLC
LSE:GETB
|
UK | GBX14.94 Million |
|
Bentley Capital Ltd
AU:BEL
|
Australia | AU$1.22 Million |
|
Christie Group plc
LSE:CTG
|
UK | GBX24.79 Million |
Liability Composition Analysis (2010–2025)
This chart breaks down Valion Bio Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see VBIO current and non-current assets.
Liquidity & Leverage Metrics
Valion Bio Inc Total Liabilities Ratios Explained
Valion Bio Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.11 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.73 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.63 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Valion Bio Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Valion Bio Inc (2010–2025)
The table below shows the annual total liabilities of Valion Bio Inc from 2010 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $14.81 Million | +5344.85% |
| 2024-12-31 | $272.00K | -82.75% |
| 2023-12-31 | $1.58 Million | -29.76% |
| 2022-12-31 | $2.25 Million | +27.27% |
| 2021-12-31 | $1.76 Million | -34.86% |
| 2020-12-31 | $2.71 Million | +314.70% |
| 2019-12-31 | $653.00K | +84.71% |
| 2017-12-31 | $353.52K | -55.85% |
| 2016-12-31 | $800.65K | +22.62% |
| 2015-12-31 | $652.96K | -57.64% |
| 2014-12-31 | $1.54 Million | +0.76% |
| 2013-12-31 | $1.53 Million | +37.84% |
| 2012-12-31 | $1.11 Million | +1010.00% |
| 2011-12-31 | $100.00K | -99.81% |
| 2010-12-31 | $51.70 Million | -- |
About Valion Bio Inc
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenesce… Read more